Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma explains how acute myeloid leukemia (AML) patients have been affected by the Covid-19 pandemic. 

AML is a rare aggressive cancer of the blood and bone marrow with a low 5-year survival rate. Standard treatment involves intense, high-dose chemotherapy. Relapsed and refractory AML are common. One cause of this is a mutation on the FLT3 gene, which approximately 1/3 of AML patients have.

As AML is an aggressive cancer, treatment must be done as quickly as possible. Dr. Krivoshik mentions that, with the Covid-19 pandemic, it has become more difficult to get AML patients into clinics for their treatments and follow-up procedures. He also mentions that the pandemic has exacerbated issues of availability of care and problems faced by those who are immuno-compromised.

For more information about AML and other rare cancers, visit